Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma

Nature Communications

Volumn 8, Issue , 2017, Pages

  Ju, Huai Qiang ^a,b   Ying, Haoqiang ^b   Tian, Tian ^a   Ling, Jianhua ^b   Fu, Jie ^b   Lu, Yu ^b   Wu, Min ^b   Yang, Lifeng ^c   Achreja, Abhinav ^c   Chen, Gang ^b   Zhuang, Zhuonan ^b   Wang, Huamin ^b   Nagrath, Deepak ^c   Yao, Jun ^b   Hung, Mien Chie ^b,d   DePinho, Ronald A ^b,d   Huang, Peng ^a,b,d   Xu, Rui Hua ^a   Chiao, Paul J ^b,d  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c RICE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MESSENGER RNA; PROTEIN P16; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TRANSCRIPTION FACTOR E2F; CYBA PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KRAS PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NOX4 PROTEIN, HUMAN; P16 PROTEIN, HUMAN; PROTEIN P21; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA;

BIOCHEMICAL COMPOSITION; CANCER; CELLS AND CELL COMPONENTS; ENZYME; GENE EXPRESSION; OXIDATION; SUBSTRATE;

AEROBIC GLYCOLYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN CELL; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PROTEIN FUNCTION; REGULATORY MECHANISM; UPREGULATION; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DRUG SCREENING; ENZYME ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GLYCOLYSIS; METABOLISM; MUTATION; OXIDATION REDUCTION REACTION; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENZYME ASSAYS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NADP; NADPH OXIDASE 4; NADPH OXIDASES; NF-KAPPA B; OXIDATION-REDUCTION; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85013778060     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14437     Document Type: Article

References (42)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. Bardeesy, N. & DePinho, R. A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 897-909 (2002).
3. Schutte, M. et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57, 3126-3130 (1997).
4. Chang, Z. et al. Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin. Cancer Res. 19, 549-559 (2013).
5. Chang, Z. et al. Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS ONE 9, e101452 (2014).
6. Aguirre, A. J. et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112-3126 (2003).
7. Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012).
8. Hu, Y. et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res. 22, 399-412 (2012).
9. Baracca, A. et al. Mitochondrial complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochim. Biophys. Acta 1797, 314-323 (2010).
10. Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107, 8788-8793 (2010).
11. Boland, M. L., Chourasia, A. H. & Macleod, K. F. Mitochondrial dysfunction in cancer. Front. Oncol. 3, 292 (2014).
12. Chiaradonna, F., Gaglio, D., Vanoni, M. & Alberghina, L. Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts. Biochim. Biophys. Acta 1757, 1338-1356 (2006).
13. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956).
14. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
15. Brown, D. I. & Griendling, K. K. Nox proteins in signal transduction. Free Radic. Biol. Med. 47, 1239-1253 (2009).
16. Griendling, K. K., Sorescu, D. & Ushio-Fukai, M. NAD(P)Hoxidase: role in cardiovascular biology and disease. Circ. Res. 86, 494-501 (2000).
17. Block, K. & Gorin, Y. Aiding and abetting roles of NOX oxidases in cellular transformation. Nat. Rev. Cancer 12, 627-637 (2012).
18. Mochizuki, T. et al. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 25, 3699-3707 (2006).
19. Edderkaoui, M. et al. NADPH oxidase activation in pancreatic cancer cells is mediated through Akt-dependent up-regulation of p22phox. J. Biol. Chem. 288, 36259 (2013).
20. Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567-571 (2010).
21. Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C. & Martins, C. P. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature 531, 110-113 (2016).
22. Liu, N., Furukawa, T., Kobari, M. & Tsao, M. S. Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am. J. Pathol. 153, 263-269 (1998).
23. Lu, W. et al. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol. 10, e1001326 (2012).
24. Hammoudi, N., Ahmed, K. B., Garcia-Prieto, C. & Huang, P. Metabolic alterations in cancer cells and therapeutic implications. Chin. J. Cancer 30, 508-525 (2011).
25. Chiarugi, A., Dolle, C., Felici, R. & Ziegler, M. The NAD metabolome--a key determinant of cancer cell biology. Nat. Rev. Cancer 12, 741-752 (2012).
26. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20 (2008).
27. Chen, J. Q. & Russo, J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim. Biophys. Acta 1826, 370-384 (2012).
28. Fan, J. et al. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510, 298-302 (2014).
29. Ling, J. et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21, 105-120 (2012).
30. DeGregori, J. & Johnson, D. G. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr. Mol. Med. 6, 739-748 (2006).
31. Bardeesy, N. et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl Acad. Sci. USA 103, 5947-5952 (2006).
32. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
33. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512 (1999).
34. Bryant, K. L., Mancias, J. D., Kimmelman, A. C. & Der, C. J. KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 39, 91-100 (2014).
35. Wallace, D. C. Mitochondria and cancer: Warburg addressed. Cold Spring Harb. Symp. Quant. Biol. 70, 363-374 (2005).
36. Garten, A., Petzold, S., Korner, A., Imai, S. & Kiess, W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 20, 130-138 (2009).
37. Ju, H. Q. et al. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Lett. 379, 1-11 (2016).
38. Lee, K. M., Yasuda, H., Hollingsworth, M. A. & Ouellette, M. M. Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab. Invest. 85, 1003-1012 (2005).
39. Melisi, D. et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J. Natl. Cancer Inst. 103, 1190-1204 (2011).
40. Yang, L. et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol. Syst. Biol. 10, 728 (2014).
41. Zhao, H. et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife 5, e10250 (2016).
42. Ju, H. Q. et al. Redox regulation of stem-like cells though the CD44v-xCT axis in colorectal cancer: mechanisms and therapeutic implications. Theranostics 6, 1160-1175 (2016).